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A cluster of protracted migratory polyarthritis involving
four adult family members occurred in January 2000 after a
brief overnight outing in a rural area of Venezuela.
Laboratory testing demonstrated Mayaro virus as the
cause of the cluster. These results documented the first
human cases of Mayaro virus in Venezuela. 
M
ayaro virus (MAYV), the cause of Mayaro fever, is a
member of the genus Alphavirus, family
Togaviridae, and is closely related to Chikungunya,
O’nyong-nyong, Ross River, Barmah Forest, and Sindbis
viruses (1–3). Infection by these viruses produce similar
clinical illnesses in humans (4–8). Mayaro fever is typical-
ly a denguelike acute febrile illness 3–5 days in duration,
characterized by headache, retroorbital pain, arthralgias,
arthritis, myalgias, vomiting, diarrhea, and rash (8).
However, joint involvement in Mayaro fever may persist
for several months and in some cases precede the fever.
Moderate-to-severe polyarthritis, occasionally incapacitat-
ing, is a prominent feature of the disease (8).
MAYV is enzootic in South America, where the sus-
pected vectors are forest-dwelling Haemagogus mosqui-
toes, and the vertebrate hosts are marmosets and other
nonhuman primates (8). Most human cases occur sporadi-
cally and involve persons who work or reside in humid
tropical forests (8,9). Nevertheless, several small out-
breaks of Mayaro fever have been described in residents of
rural communities of the Amazon region of Brazil, Bolivia,
and Peru (8–10). Airborne transmission has been reported
among laboratory personnel (11). Although MAYV is
enzootic in several South American countries, this report
describes the first human cases of Mayaro fever in
Venezuela. The cases occurred among members of the
same family after a single day’s exposure to a semirural
forested area. The observations we report were made in
response to the Ministry of Health’s request to determine
the cause of the cluster of cases.
The Study
Clinical cases resembling dengue fever were studied in
the vicinity of Padrón Agriculture Station, in Miranda
State, north-central Venezuela (10°13′22″ N; 66°17′56″ W;
50 m elevation), a location where entomologic and epi-
demiologic studies on Venezuelan equine encephalitis
virus (VEEV) and other arboviruses were conducted from
1997 to 1998 (12). This area, originally covered by low-
land tropical rain forest, was converted into cacao
(Theobroma cacao) plantations. Indigenous tall trees
(Erythrina poeppigiana, Ceiba pentandra, Ficus sp., Hura
crepitans, Bauhinia sp.), were preserved so that the area
resembled a natural forest habitat. The mean temperature
and annual rainfall were 27.2°C and 2,324 mm, respective-
ly, with the rainy season normally lasting from May to
December.
Four adult members of the same family (age range
26–58 years), spent a single night together in early
January 2000 near the Padrón Agriculture Station. While
sharing an outdoor dinner, they were frequently bitten by
mosquitoes. Three days later, all four had a sudden onset
of malaise, fever (up to 40°C), retroocular pain, general-
ized headache, conjunctival suffusion, flushing of the face
and neck, myalgias, and severe incapacitating polyarthral-
gias and polyarthritis which mainly involved the small
joints of the hands, wrists, ankles, and toes. Joints became
swollen and tender, but effusion was not evident. Pain was
intense and worsened with motion. Limbs felt weak and
very sensitive to touch. Joint stiffness in the morning and
after inactivity was a prominent complaint. On day 5 of
illness, a rapidly spreading maculopapular rash devel-
oped, which involved neck, trunk, and limbs. The rash
persisted for 2 days, followed by desquamation. In three
of the patients, painful cervical, preauricular, and retroau-
ricular lymphadenopathies occurred and lasted approxi-
mately 2 weeks. Beyond week 2 of illness, only severe
joint symptoms and lower limb hyperesthesias persisted,
but they steadily resolved during a 6-month period.
Clinical laboratory results were unremarkable except for a
transient and mild increase in erythrocyte sedimentation
rate and serum levels of alanine aminotransferase, and a
moderate lymphocytosis.
Serum samples were obtained 3 months after onset of
symptoms, when the patients were first seen at consulta-
tion by one of the authors. Samples were also collected an
additional 3 months after the initial samples were collect-
ed. The patients’ initial signs and symptoms resembled a
classical febrile syndrome, and the patients had a history of
suspected risk for arboviral infection. Therefore, all sam-
ples were tested initially at a 1:100 dilution for
immunoglobulin (Ig) M antibodies to MAYV; VEEV;
dengue viruses (DENV) 1, 2, 3, and 4; yellow fever virus
(YFV); and Oropouche virus (OROV) by using an IgM
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(MACEIA) (9,12). Reactive samples were subsequently
retested for IgM antibody at serial dilutions ranging from
1:200 through 1:102,400 to determine endpoint titers.
Serum samples were also tested by an indirect ELISA for
IgG antibodies to the above-mentioned viruses (9,13). A
patient with MAYV disease was defined as a person with
compatible clinical illness, for whom IgM antibody titers
to MAYV and VEEV were >400 and <100, respectively. 
Results
Serologic results indicated that three of the four family
members had a MAYV viral infection. Assay of serum
samples obtained 3 months after onset of symptoms from
the three members showed high specific Mayaro viral IgM
antibody ranging from 3,200 to 6,400 and IgG antibody
titers ranging from 6,400 to 12,800 (Table). Testing of
samples from the fourth patient were positive for MAYV
IgG antibody only. Subsequent samples taken approxi-
mately 3 months later were IgM negative but remained
positive for MAYV IgG antibody. All patients were nega-
tive for VEEV IgM antibody but had VEEV IgG antibody
ranging from 100 to 800. Assay results for DENV and
OROV IgM and IgG were negative. Simlarly, the patients
were negative for YFV IgM antibody but had IgG antibody
to this virus.
Conclusions
MAYV has not been isolated in Venezuela, but isolates
have been obtained from humans, wild vertebrates, and
mosquitoes in Colombia, Brazil, Suriname, Guyana,
French Guiana, Peru, United States, and Bolivia
(2,8–10,14–17). In addition, serologic survey data suggest
that MAYV infection is relatively common among humans
in rural populations of northern South America and the
Amazon River basin (2,8,9,14–16). This virus is believed
to be maintained in a sylvan cycle involving wild verte-
brates, such as nonhuman primates and possibly birds, and
Haemagogus mosquitoes (2,8,18). Three species of that
genus, H. celeste, H. equinus, and H. lucifer, have recent-
ly been identified in the area where the Venezuela patients
acquired MAYV infection (12). Also, the red howler mon-
key (Alouatta seniculus), a suspected host of MAYV in
nature, is common in the area. Thus, the results of this
study suggest that these first documented cases of Mayaro
fever in Venezuela were acquired during an overnight out-
ing in a rural area where MAYV may have been circulat-
ing in a cycle involving Haemagogus mosquitoes and red
howler monkeys. 
Convalescent-phase serum samples from an additional
unrelated patient (a 40-year-old woman who lived in a
nearby rural location), obtained approximately 4 months
after she had recovered from a self-limited febrile illness
with polyarthritis similar to that described in the patients
involved in this report, showed high (25,600) MAYV IgG
antibody titers. These samples were negative for IgM anti-
body, however, which provides further evidence that
MAYV was enzootic in the area.
As observed in this study, Mayaro fever cases are usu-
ally sporadic and occur in persons with a history of recent
activities in humid tropical forests (4,8,9,19). Typically,
Mayaro fever ensues approximately 1 week after infection
(4,8). However, shorter incubation periods, similar to those
observed in these Venezuelan cases, are occasionally
observed. Members of the family described in this out-
break had symptoms and clinical courses consistent with
previously documented MAYV patients. Abrupt onset of
fever, frontal headaches, myalgias, and incapacitating
arthralgias were predominant complaints. A maculopapu-
lar rash, also a common manifestation in up to 90% of chil-
dren and 50% of adults (4,8,9,18), was prominent in these
patients, lasting 2 days and followed by desquamation. Up
to one third of patients initially have nausea, vomiting, and
diarrhea (4,8,9,18,19), but these symptoms were not expe-
rienced in this family. 
Little information is available on the kinetics of MAYV
IgM antibodies for Mayaro fever patients during long-term
follow-up examinations. While obtaining acute-phase
blood samples from the patients in this study was not pos-
sible, existing data indicate that detectable IgM antibody
develops after viremia subsides, which is usually 4–5 days
after the onset of symptoms (9,19). Our data indicated that
Mayaro Fever, Venezuela
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Table. Mayaro and Venezuelan equine encephalitis viral IgM and IgG antibodies demonstrated by an antibody-capture ELISA in serum 





c  Late convalescent–phase
d 
MAYV  VEEV  MAYV  VEEV 
Patient  IgM  IgG  IgM  IgG  IgM  IgG  IgM  IgG 
1  3,200  12,800  0  400  0  12,800  0  400 
2  6,400  12,800  0  800  0  12,800  0  800 
3  6,400  6,400  0  400  0  6,400  0  100 
aMAYV, Mayaro virus; VEEV, Venezuelan equine encephalitis virus; Ig, immunoglobulin; ELISA, enzyme-linked immunosorbent assay. 
bReciprocal of highest serum dilution at which a positive result occurred. 
cThree months after onset of illness. 
dSix months after onset of illness. IgM antibody persisted for >3 but <6 months for our
patients. These are the first documented data on the persist-
ence of IgM antibody following a Mayaro viral infection
and will be useful for interpreting diagnostic test results.
To our knowledge, this is the first report of human cases of
MAYF in Venezuela and, therefore, further documents the
public health importance of this disease.
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